In Reply Ms Msefula and colleagues raise an important point regarding inclusion of tests and therapies in the Phoenix Sepsis Score that, based on the global survey performed by the Pediatric Sepsis Definition Task Force, may not be universally available. Msefula and colleagues have an associated concern that lack of these tests and therapies may lead to an underestimation of sepsis prevalence in lower-resource settings, substantiated by the prevalence rates we reported in lower- vs higher-resource settings (5.4%, vs 7.1%).
